INC Research Names Vice President, Regulatory Affairs and Strategic Drug Development

Wayne Whittingham Joins to Lead Global Regulatory and Strategic Consulting Group
RALEIGH, N.C.--(Business Wire)--
INC Research®, Inc., a therapeutically focused contract research organization
(CRO) with a process for delivering reliable results, today announced the
appointment of Wayne Whittingham, as vice president, Regulatory Affairs and
Strategic Drug Development. In this role, Whittingham is able to leverage his
career experiences in federally regulated environments, technical regulatory
expertise and project management skills to enhance and expand the capabilities
of his team to better serve the overall global development needs of INC Research
customers.

INC Research`s Regulatory Services team has a history of providing a
comprehensive array of operational regulatory and medical writing support for
regulatory submissions. The team works closely with the company`s growing
Strategic Consulting Group (SCG) to offer customers specialized expertise in
global regulatory issues. INC Research`s SCG, comprised of in-house MDs, PhDs
and MBAs, are able to maximize the value of its customers` intellectual property
and portfolio content. Whittingham will provide leadership to both of these
groups for a more synergistic approach to drug development.

"Wayne has the right mix of global regulatory affairs and hands-on clinical
project management experience to help our customers navigate a highly regulated
and increasingly complex drug development environment," said Alistair Macdonald,
general manager, Global Services at INC Research. "By including the role of
regulatory affairs throughout each phase of our Trusted Process, Wayne and his
team will continue to maximize the success of our customers` global regulatory
submissions."

As a RAC Certified Regulatory Professional, Whittingham has more than 20 years
direct experience in regulatory affairs and project management. Previously, he
held senior management roles where he developed regulatory strategies and
provided regulatory guidance to multidisciplinary projects with various
pharmaceutical companies, including a venture capital firm that specialized in
seed stage investments. He also held the international regulatory affairs role
for a global pharmaceutical company and worked within the FDA for six years in
CBER, CDER and CFSAN.

"I am thrilled to be able to apply my expertise to INC Research`s
well-established team," said Whittingham. "The intersection of regulatory
affairs and strategic consulting helps INC Research provide highly experienced
and comprehensive guidance to propel our customer`s R&D efforts."

For more information on INC Research`s Regulatory Services and Strategic
Consulting Group, visit www.incresearch.com

About INC Research® Inc.

INC Research is a therapeutically focused contract research organization with a
high performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to INC
Research for a complete range of customized Phase I through Phase IV programs in
therapeutic areas of specialty, and in innovative pediatric and women`s health
trials. The company`s The Trusted Process® methodology and therapeutic foresight
leads customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, North Carolina. For more
information please visit www.incresearch.com.

for INC Research
Kelly Foster, + 1 619-224-1261
kelly@johnkellyfoster.com

Copyright Business Wire 2009